Getting a new product to market is expensive. There are a variety of studies and research that point to a wide array of costs, but generally speaking, it costs nearly $3 billion dollars to bring a new drug to market. Yes, you read that correctly. Beyond this, the success rate of a new compound to...
Running a Study
The new standard in clinical care Electronic Medical Records In the past several decades, Electronic Medical Records (EMR) have become standard in clinical care in the United States and many other countries, while Electronic Data Capture (EDC) systems have become standard in global pharmaceutical trials. Naturally, the industry has been highly focused on the tantalizing...
Running a Study
Why use EDC if eSource has the endpoint data? In the CRIO article, Automate the protocol with eSource, we described how CRIO eSource automates the protocol, building compliance at the point of capture. CRIO is often asked if we can send the data to the EDC. The answer is yes, if the EDC system’s API...
Running a Study
Hiding in plain sight – CRIO eSource is the biggest opportunity for sponsors. While the clinical research industry has automated many processes, there is one area that is still mostly paper-bound. This is the source of one of the greatest inefficiencies in research today. Automating this one process could drive 20% cost savings in a...
Running a Study
CRIO’s integrated eSource-EDC model revolutionizes both the data entry process at the site level and the monitoring process from the CRO perspective. According to a third party survey of CRAs who have used CRIO, CRAs agreed by a margin of 23:1 that this new model would increase overall trial efficiency, improve data quality, and enhance...
Running a Study
Over 13,000 protocols have gone through the CRIO system, and in the vast majority of them, CRAs have used CRIO to monitor source. We’ve always heard from our sites that their CRAs love the system, but now we have proof. According to a third party survey of CRAs who have used CRIO, by a healthy...
Networks are brick and mortar businesses by definition, but their differentiation lies in their ability to incorporate and optimize technology in every step of the workflow. No single technology vendor will be able to service the full gamut of needs. Instead, leadership teams should select and configure optimal solutions for different stages of the value...
Running a Site
There are plenty of instances where institutional capital goes into a sector, only to fizzle out. Why are we confident that the site network trend is real, and not hype? We’ve identified 4 main levers of revenue and profit growth for network consolidation. In order, from the “quick hit” to the heaviest lift: Business Development...
Running a Site
Valuation of site for purchase by site networks As site networks compete with each other to purchase clinical research sites, certain valuation standards have emerged. For sites that achieve a scale threshold, an exit is possible at a multiple of the site’s EBITDA. EBITDA stands for earnings before taxes, interest, depreciation and amortization, and it’s...
Running a Site
In a 2019 CRIO eBook, “Scaling and Innovating: The Consolidation and Reinvention of Clinical Research Sites” we explored the emerging trend of clinical research site consolidation. Our predictions were prescient. Today, the number of institutional investors in the space has increased more than 7-fold since 2015, with no sign of abating. We at CRIO predict...
Running a Study
Overview With 9 locations in Texas, California and Louisiana, Benchmark Research is the world’s leading vaccine network. Benchmark has performed over 10,000 studies on over 40,000 subjects and has received numerous awards, including being a five-time recipient of the Best Clinical Trial Site/Network award from the World Vaccine Congress. Challenge Historically, Benchmark used paper charts...
CRIO Company News
BOSTON, MA – November 3, 2022 – CRIO, the industry’s leading eSource provider, announces the appointment of Dr. Margaretta Nyilas to its Board of Directors, effective immediately. Dr. Nyilas is a biopharmaceutical executive with over twenty years of diverse global industry experience, formerly at Otsuka Pharmaceuticals, Bristol Myers Squibb and Click Therapeutics. She has a...
